Arcturus Therapeutics Announces Strategic Collaboration with Thermo Fisher Scientific to Advance ARCT-032 for Cystic Fibrosis

Arcturus Therapeutics entered a strategic collaboration with Thermo Fisher Scientific to support the Phase 3 development and potential commercialization of ARCT-032, its investigational mRNA therapy for cystic fibrosis. The agreement leverages Thermo Fisher's Accelerator solutions for manufacturing and clinical research, with Phase 3 activities expected to be conducted via Thermo Fisher's PPD business if Phase 2 results are positive.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.